March 1, 2020
Study Reports on Use of Corindus’ CorPath GRX Robotic System for Neuroendovascular Procedures
March 1, 2020—Thomas Jefferson University in Philadelphia, Pennsylvania, announced that a study led by Pascal Jabbour, MD, Chief of the institution’s Division of Neurovascular Surgery and Endovascular Neurosurgery, demonstrated the safety and effectiveness of the CorPath GRX robotic-assisted surgical platform (Corindus Robotics Vascular, Inc.) to aid surgeons during diagnostic cerebral angiograms and transradial carotid artery stenting. The study was published by Kalyan Chekravarthy Sajja, MD, et al online ahead of print in the Journal of NeuroInterventional Surgery.
In the study, Dr. Jabbour and colleagues tested the use of the next-generation CorPath GRX platform on 10 patients undergoing either a diagnostic cerebral angiogram or carotid artery stenting. All of the procedures were successful, with no complications encountered.
Dr. Jabbour commented in the press release, “This technology could be groundbreaking, acting as a precursor for remote stroke interventions.” Noting that time is of the essence when a patient experiences a stroke, Dr. Jabbour explained that patients living in remote geographic areas have further to travel for stroke intervention by the time they arrive at a stroke center, it is often too late for treatment to prevent permanent damage. He said, “These robots would allow us to intervene remotely on those patients. The patient would still be in the community, and I would be sitting here at Jefferson controlling the robot.”
Physicians at Thomas Jefferson’s Sidney Kimmel Medical College are pioneering the use of robotics in neuroendovascular procedures. According to the announcement, Jefferson is the first center in the country to perform robotic transradial carotid stenting. Currently, robots are only approved by the FDA for use in certain general surgery procedures and in interventional cardiology procedures.
The benefits of using robots in neuroendovascular procedures include more precise control over the microcatheter and the microwire, as well as less exposure to radiation from X-rays because the robot can be operated from a separate room just outside the surgical suite.
In February 2019, Corindus Vascular Robotics announced that it is seeking premarket clearance from the FDA for a neurovascular intervention indication for its CorPath GRX system.
Dr. Jabbour concluded, “The next generation of robots are ready to be launched, and as soon as they are approved by the FDA, we will be able to move to the next step, which is performing interventions inside the brain. Jefferson will be on the front line of this technology, training the new generation of fellows on how to use these robots before anyone else in the country.”